3H Health Investment

3H Health Investment is a private equity firm based in Hong Kong that specializes in the healthcare sector in China. The firm focuses on investing in various segments of the healthcare industry, including healthcare devices and diagnostics, healthcare services, pharmaceuticals, and healthcare products. With a proactive and innovative investment approach, 3H Health Investment leverages its deep understanding of the Chinese market and extensive industry connections to identify and create value in investment opportunities. The firm's expertise in fund management further enhances its ability to navigate the complexities of the healthcare landscape in China.

Sheng Li

Founding Managing Partner

Shunlong Wang

Chairman and Founder

Minchuan Wang

Partner

21 past transactions

Timberlyne Therapeutics

Series A in 2025
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company that develops and commercializes revolutionary medicines for autoimmune illnesses. The company utilizes its team's experience in drug development to secure top-tier assets focused on promising targets, and implementing them in disease areas with considerable unmet needs.

Angitia Biopharmaceuticals

Series C in 2024
Angitia Biopharmaceuticals is a global biotechnology company dedicated to discovering and developing innovative therapeutics for serious musculoskeletal diseases. The company focuses on researching and creating breakthrough therapies aimed at treating conditions affecting bones, muscles, and joints. By prioritizing the development of novel drugs, Angitia Biopharmaceuticals aims to improve patient outcomes and facilitate recovery from severe musculoskeletal ailments.

Angitia Biopharmaceuticals

Series B in 2023
Angitia Biopharmaceuticals is a global biotechnology company dedicated to discovering and developing innovative therapeutics for serious musculoskeletal diseases. The company focuses on researching and creating breakthrough therapies aimed at treating conditions affecting bones, muscles, and joints. By prioritizing the development of novel drugs, Angitia Biopharmaceuticals aims to improve patient outcomes and facilitate recovery from severe musculoskeletal ailments.

Chamlion

Series B in 2023
Chamlion provides end-to-end digital dentistry solutions based on 3D printing technology.

Chenglian Technology

Series B in 2023
Chamlion 3D is a national high-tech enterprise incubated and established by the Additive Manufacturing Institute of Nanjing University of Aeronautics and Astronautics. Digital solutions for dental 3D printing, leading the digital transformation and upgrading of the industry. Chenglian Technology is deeply engaged in the field of dentistry, with its in-depth understanding of the industry and rich product development.

Alebund Pharmaceuticals

Series C in 2023
Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.

Yuanyin Bio

Series A in 2022
Yuanyin Bio is a biotechnology company focuses on the research and application of circular RNA technology in the field of innovative drugs and therapies, builds a robust pipeline of preventive and therapeutic new drugs, and is dedicated to addressing clinically unmet disease needs. They serve in the field of innovative drugs and therapies. It establishes a pipeline of preventive and therapeutic new drugs and is committed to solving clinically unmet disease needs.

Edge Medical Robotics

Series C in 2021
Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.

Tripod Preclinical Research

Venture Round in 2021
Tripod Preclinical Research is a Contract Research Organization that specializes in providing preclinical research services to the biopharmaceutical and medical device industries. The company offers a comprehensive range of services, including drug safety evaluation for new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Tripod's expertise encompasses non-human primate disease models, pharmacological efficacy studies, early drug evaluation, and Good Laboratory Practices (GLP) toxicology. Additionally, the organization supports translational medicine and clinical trials, along with biological analysis and the management of biological sample banks. By delivering these services, Tripod aids drug developers and researchers in advancing their projects through the critical early stages of research and development.

Vision X

Series B in 2021
Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.

Alebund Pharmaceuticals

Series B in 2021
Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.

Kanova

Series B in 2021
Kanova is a biopharmaceutical company dedicated to the development of therapeutic antibodies and innovative combination therapies targeting immuno-oncology and autoimmune diseases. The company offers a biomedical technology service platform that supports pharmaceutical research and production in biotechnology. It specializes in antibody-based drugs that enhance immune system function, along with providing technical consultation and drug quality inspection services. By focusing on these areas, Kanova aims to help clients improve drug quality and advance the discovery of new biomedicine efficiently.

Reliable Med

Series A in 2021
Reliable Med is a developer and provider of clinical mass spectrometry equipment designed for in vitro diagnostic (IVD) tests. The company focuses on addressing the needs of the medical industry by offering high-end clinical mass spectrometry devices and IVD detection kits. By doing so, Reliable Med aims to enhance the efficiency and accuracy of patient diagnoses within the healthcare sector.

EdiGene

Series B in 2021
EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

MicroTech Medical

Series D in 2020
MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.

Hemu (China) Biological Engineering

Series B in 2020
Hemu (China) Biological Engineering is a Chinese blood vessel intervention medical equipment firm.

EdiGene

Series B in 2020
EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

Edge Medical Robotics

Series B in 2020
Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.

Shenqi Medical

Series C in 2020
Shenqi Medical specializes in the research and manufacturing of innovative medical devices, primarily catering to the healthcare sector in China. The company offers a diverse range of products aimed at addressing cardiovascular issues, structural heart disease, and peripheral and neurovascular conditions. By focusing on minimally invasive surgical technologies, Shenqi Medical aims to enhance the safety and reliability of cardiovascular procedures, ultimately improving patient outcomes.

Citrine Medicine

Series A in 2020
Citrine Medicine is a rare disease-focused pharmaceutical firm.

MicroPort CardioFlow

Private Equity Round in 2020
Shanghai MicroPort CardioFlow Medtech Co., Ltd., established in 2015, is a medical device company specializing in advanced minimally invasive therapies for structural heart diseases. As a subsidiary of MicroPort Scientific Corporation, it focuses on the research, development, and commercialization of innovative solutions for valvular heart diseases. The company's product portfolio includes VitaFlow, VitaFlow Liberty, Alwide Plus, and a range of transcatheter aortic valve implantation (TAVI), transcatheter mitral valve (TMV), and surgical valve products, along with procedural accessories. Primarily operating in China, MicroPort CardioFlow emphasizes the importance of improving patient quality of life through reliable and affordable healthcare solutions while maintaining a global vision for its products and services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.